| Document |
Document Title |
|
WO/2017/180064A1 |
The invention relates to medicine and veterinary applications, in particular, as a means for effective control of acute and/or chronic pain, and may be used in emergency medicine for the treatment of acute and/or chronic pain, including ...
|
|
WO/2017/178950A1 |
Disclosed herein is an improved 4+4 solution phase synthesis of Lanreotide acetate. The process comprises coupling of two suitably protected tetrapeptide fragments which on deprotection, oxidation, followed by treatment with acetic acid ...
|
|
WO/2017/179647A1 |
A peptide is provided which has a binding inhibitory function that inhibits binding between amylospheroids (ASPD) and neurons. The polypeptide, represented by expression (I) or (II), is synthesized, isolated or purified. X1X2X3X4 (I) In ...
|
|
WO/2017/175107A1 |
Disclosed herein is an improved 4+4 solution phase synthesis of octreotide acetate. The process comprises coupling of two suitably protected tetrapeptide fragments which on deprotection, oxidation, and treatment with acetic acid provides...
|
|
WO/2017/176460A2 |
Neuropeptide S receptor agonists are provided. The NPS agonists include trimeric, tetrameric, pentameric or hexameric peptidomimetic analogs exhibiting affinity for and activity at the neuropeptide S receptor. The peptidomimetic molecule...
|
|
WO/2017/170637A1 |
The purpose of the present invention is to provide a compound that has at the C-terminus a functional group utilizable for formation of a complex and that exhibits cell toxicity. Provided by the present invention is a peptide derivative ...
|
|
WO/2017/170924A1 |
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...
|
|
WO/2017/160124A2 |
The present invention relates to a recombinant expression vector for producing a water-soluble norovirus vaccine, and more particularly, to a recombinant expression vector for producing a water-soluble norovirus vaccine, and a method for...
|
|
WO/2017/160118A2 |
The present invention relates to a novel peptide for improving the expression efficiency of a target protein, and to a fusion protein including same. A novel peptide according to the present invention may improve the expression efficienc...
|
|
WO/2017/161144A1 |
The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The prese...
|
|
WO/2017/159554A1 |
The invention provides a crystal of glutathione having excellent flowability and pulverizability, and a method for producing the same. The invention relates to a crystal of reduced-form glutathione, wherein the average crystal thickness ...
|
|
WO/2017/159555A1 |
The purpose of the invention is to provide: a crystal of reduced-form glutathione in which the content of impurities, particularly L-cysteinyl-L-glycine, is reduced; and a method for producing the same. The invention relates to a crystal...
|
|
WO/2017/157213A1 |
The present invention relates to a compound represented by formula (I), chemical synthesis preparation of dual-functional conjugates capable of inhibiting tumors and tumor metastasis, and tumor resistance effects. In the present inventio...
|
|
WO/2017/156071A1 |
The present technology relates to cyclic keto-amide compounds of general formulae I to XXXII, compositions and kits thereof as calpain modulators and methods useful for the treatment of various diseases or disorders such as fibrotic dise...
|
|
WO/2017/156403A1 |
Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.
|
|
WO/2017/148967A1 |
The invention provides novel compounds having the general formula (I) wherein wherein R1, R2, R3, R4, R5, R6, R7, R3, R8, R9, R10, R11, R12 and R23 are as described herein, compositions including the compounds and methods of using the co...
|
|
WO/2017/150549A1 |
The present invention pertains to a compound, etc., from which is obtained a radiolabeled drug capable of reducing accumulation in the kidneys from early administration. [1] A compound, etc., represented by formula (1); [2] a compound, e...
|
|
WO/2017/151886A1 |
The disclosure provides methods of preventing or treating pulmonary arterial hypertension (PAH) in a mammalian subject, reducing risk factors associated with PAH, and/or reducing the likelihood or severity of PAH. The methods comprise ad...
|
|
WO/2017/150997A1 |
The subject of the invention is a new compound of the following chemical formula: ABZ1 -Dap(02(Cbz))2-Dap(01 )3-Dap(02)4-Arg5-ANB6-NH2 where: ABZ stands for 2-aminobenzoic acid; DAP stands for diaminopropanoic acid (Dap) derivatives, mod...
|
|
WO/2017/151587A1 |
The present disclosure relates to compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the invention include aza-peptide aldehyde and ketone ...
|
|
WO/2017/150732A1 |
It has become clear that if a peptide having a thiol group near an amino group, and having, at the N-terminal, an amino acid residue, which introduced a specific protective group into the thiol group and amino group, undergoes translatio...
|
|
WO/2017/148964A1 |
The invention provides serine protease HTRA1 inhibiting compounds having the general formula (I) wherein R 2, R 3, R 4, R 5, R 6, R 7, R 3, R 8, R 10, R 11and R 23 are as described herein. These compounds are suitable for the treatment o...
|
|
WO/2017/151617A1 |
Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making ...
|
|
WO/2017/150327A1 |
The present invention addresses the problem of providing a food material that is added to food to promote in-brain secretion of neurotrophins including BDNF, and that can endow the food with a brain function improvement function and a cr...
|
|
WO/2017/143449A1 |
The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC a...
|
|
WO/2017/140997A1 |
The invention relates to a lipid nanoparticle comprising an SDKP peptide conjugate or a biological peptide analog thereof, a method for obtaining said lipid nanoparticle, and the cosmetic use thereof as an anti-wrinkle agent or skin rest...
|
|
WO/2017/142372A1 |
The present invention relates to an antibody affinity ligand for use in purifying antibodies. In the present invention, it was revealed that an inter-amino acid site between amino acid residues existing at first and second positions towa...
|
|
WO/2017/142254A1 |
The present invention provides a peptide which shows a hair growth-promoting activity. The peptide of the present invention promotes the growth of follicular cells and increases the expression of a hair growth-related growth factor and h...
|
|
WO/2017/138013A1 |
In accordance with the present subject matter there is provided a compound of Formula I wherein, R1 is substituted C1 to C10 alkyl; and R2 is substituted C1 to C10 alkyl, a process for preparing a compound of Formula I, and a gel compris...
|
|
WO/2017/132771A1 |
Formulations for treating burns and burn wound healing comprising a Granzyme B inhibitor and a pharmaceutically acceptable carrier, and methods for treating burns and for burn wound healing using the formulations.
|
|
WO/2017/136348A1 |
Disclosed is a new process for preparing dipyrrolidine peptide compounds such as, for example, GLYX-13. Advantageously, the process may be industrially scalable and cost-effective and use less toxic reagents and/or solvents. Further, the...
|
|
WO/2017/130148A1 |
The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need there...
|
|
WO/2017/130884A1 |
The present invention provides novel technology for improving the storage stability of peptides such as glutathione. The present invention relates to a peptide-containing composition that comprises a peptide and an alkaline mineral carri...
|
|
WO/2017/132395A1 |
In various embodiments methods and compositions to increase the rate and/or activity of ligation reactions catalyzed by a sortase. In certain embodiments reagents are provided that comprises, inter alia, a polypeptide comprising an amino...
|
|
WO/2017/132547A1 |
Disclosed herein is a personalized immunotherapy composition for a subject having a disease or condition, including therapeutic vaccine delivery vectors and methods of making the same comprising gene expression constructs expressing fram...
|
|
WO/2017/127007A1 |
The invention discloses a method for the preparation of a peptide by liquid phase coupling of two fragments, an N-terminal fragment and a C-terminal fragment of the desired peptide, wherein the C-terminal fragment is protected on its C-t...
|
|
WO/2017/125933A1 |
The present invention provides nanoparticle conjugates incorporating the self- assembling module diphenylalanine (FF) dipeptide into a bioactive moiety. The conjugate self-assembles to form distinct nanometric structures such as nanosphe...
|
|
WO/2017/123634A1 |
This invention provides composition and methods to prevent, treat or alleviate a symptom of ulcerative colitis comprising administering to a patient dolcanatide.
|
|
WO/2017/123977A1 |
Methods of treating osteonecrosis in a subject are provided. In some embodiments, the method comprises administering to a subject having or suspected of having osteonecrosis a pharmaceutical composition comprising a conjugate of an LLP2A...
|
|
WO/2017/121649A1 |
The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-l,3-diaza- spiro-[4.5]-decane derivatives of general formula (I), their preparation and their use in medicine, particularly in the treatment of pain.
|
|
WO/2017/120470A1 |
The disclosure provides methods of preventing or treating DMD in a mammalian subject, reducing risk factors associated with DMD, and/or reducing the likelihood or severity of DMD. The methods comprise administering to the subject an effe...
|
|
WO/2017/120350A1 |
This application is directed to compositions comprising of isolated aggregated peptide constructs that are formulated with inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase commonly known as statins as well as methods of trea...
|
|
WO/2017/117684A1 |
The present invention relates to a SMAC mimetic compound and pharmaceutical compositions thereof, more specifically the present invention is directed to a Compound 1 with a following structure: (I) pharmaceutically acceptable salts there...
|
|
WO/2017/107241A1 |
Provided in the present invention are a method for preparing a polypeptide of a KPV peptide and an analogue thereof, wherein same are synthesized by a whole solid phase synthesis method, comprising the following steps: 1. using a polymer...
|
|
WO/2017/111215A1 |
The present invention relates to a composition for improving memory, learning ability and cognition. It has been identified that: a peptide, of the present invention, having a C-terminus ending with GAG, has an effect of improving memory...
|
|
WO/2017/112947A1 |
Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders or other diseases and disorders.
|
|
WO/2017/104880A1 |
The present invention provides a lactic acid bacterial strain having antibacterial activity for an antibacterial purpose, wherein lactobacillus plantarum IRWEE-01 produces high levels of various antibacterial, antifungal, and antiviral s...
|
|
WO/2017/097193A1 |
The present invention provides a method for refining a lisinopril hydride crude product by means of solvent crystallization. The method specifically comprises: adding ketones solvents into a crude product which contains lisinopril hydrid...
|
|
WO/2017/098532A1 |
The present disclosure provides crystalline carfilzomib form M1 and a process for the preparation thereof. Further disclosed are processes for the preparation of amorphous carfilzomib using crystalline form M1 as a starting material.The ...
|
|
WO/2017/099319A1 |
The present invention relates to improved peptides for inhibiting angiogenesis, Ac-RLYE and R (D) LYE, and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an activ...
|
